Subsequent Events

12 Months Ended

Dec. 31, 2018

Subsequent Events [Abstract]

Subsequent Events [Text Block]

Subsequent Events

Share Repurchase

From January 1, 2019 to March 13, 2019, the Company repurchased approximately 10.7 million shares of its common stock at a weighted-average price of $3.32 per share for a total of $35.5 million. The total amounts repurchased by the Company under the $100.0 million share repurchase program authorized by the Company’s board of directors equal approximately 19.4 million shares of its common stock for an aggregate purchase price of $61.0 million, or an average cost of $3.15 per share, including trading commissions.

CareView Modification Agreement

As further discussed in Note 9, Notes and Other Long-Term Receivables, the first principal payment and the scheduled interest payment due December 31, 2018 that were previously deferred until January 31, 2019 were subsequently deferred until March 31, 2019 under additional amendments.

Authorized Generic

As further discussed in Note 13, Intangible Assets, on March 4, 2019, the Company announced the U.S. commercial launch of an authorized generic of Tekturna, with the same drug formulation as Tekturna.